GO
Loading...

Enter multiple symbols separated by commas

CBS Swings to Profit in the Fourth Quarter

CBS swung to a profit in the fourth-quarter from a year ago period that included a major charge to write down the value of its television and radio businesses, the company said Tuesday.

CBS reported net income of $335 million, or 43 cents per share, in the October-December period. A year ago, the company reported a loss of $9.14 billion, or $12 per share. That included a charge of $9.48 billion for the asset impairment.

Adjusted to exclude items, earnings from continuing operations were $464 million, or 60 cents per share, versus $321.5 million, or 42 cents per share, a year ago.

The gain was driven by stronger results in television, outdoor advertising and publishing, which partially offset continued weakness at the company's radio unit.

Analysts, whose estimates typically exclude items, were looking for profit of 47 cents per share.

Revenue rose 2% to $3.88 billion from $3.79 billion a year ago and beat the Street's estimate of $3.83 billion.

The fourth quarter of 2005 was the first for CBS as a standalone company after it split from Viacom. The company also announced a buyback of $1.5 billion of its shares.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Greece at a standstill

    Greek Chamber of Commerce's Constantine Michalos, provides perspective on bank closures in Greece, and the biggest fears among Greeks as they await a deal on the country's debt.

  • CNBC update: Sweat in prison

    Two bombs exploded at a crowded mosque and restaurant in a central Nigerian city, killing 51 people; and David Sweat is back in prison, reports CNBC's Sue Herera.

  • Aetna, Humana CEOs talk antitrust concerns

    Aetna is buying Humana for for about $37 billion in cash and stock. Mark Bertolini, Aetna Chairman and CEO, and Bruce Broussard, Humana President and CEO, discuss the transaction and antitrust scrutiny.